Cargando…

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

BACKGROUND: Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β(2−)agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and tolerability of single doses of navafenterol were investigated in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Balaguer, Victor, Astbury, Carol, Wählby-Hamrén, Ulrika, Jimenez, Eulalia, Seoane, Beatriz, Villarroel, Cristina, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487995/ https://www.ncbi.nlm.nih.gov/pubmed/32907566 http://dx.doi.org/10.1186/s12931-020-01347-7

Ejemplares similares

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
por: Singh, Dave, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

Cardiovascular morbidity and the use of inhaled bronchodilators
por: Macie, Christine, et al.
Publicado: (2008)

Abediterol, a novel long-acting β(2)-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
por: Beier, Jutta, et al.
Publicado: (2016)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

The role of inhaled and/or nasal corticosteroids on the bronchodilator response
por: Lee, Ju Kyung, et al.
Publicado: (2010)

Inhaled Bronchodilator Use for Infants with Bronchopulmonary Dysplasia
por: Slaughter, Jonathan L, et al.
Publicado: (2014)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

Bronchodilator delivery with metered-dose inhaler during mechanical ventilation
por: Georgopoulos, Dimitris, et al.
Publicado: (2000)

Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants
por: Euteneuer, Joshua C., et al.
Publicado: (2020)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β(2)-adrenergic agonist, in asthma; a Phase II, randomized study
por: Singh, Dave, et al.
Publicado: (2014)

Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators
por: Hendrickx, Ramon, et al.
Publicado: (2017)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β(2) Adrenergic Receptor Agonist Navafenterol in Human Small Airways
por: Jude, Joseph Antony, et al.
Publicado: (2023)

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
por: Delaney, Stephen, et al.
Publicado: (2016)

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
por: Kozma, Chris M, et al.
Publicado: (2011)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
por: Pascoe, Steven, et al.
Publicado: (2016)

Responses of FEV(6), FVC, and FET to inhaled bronchodilator in the adult general population
por: Kainu, Annette, et al.
Publicado: (2009)

Inhaled bronchodilators and acute myocardial infarction: a nested case-control study
por: Lee, Chang-Hoon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uc2q92l14o1ci9b48j0k2hjibv